Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

The highly encouraging study results further MIRA's goal of submitting an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) later this year which, if granted, would allow for human clinical trials of Ketamir-2. The following findings were observed: "We are thrilled with the promising results from these preclinical trials, which demonstrate Ketamir-2's efficacy and improved safety profile over traditional ketamine," said Erez Aminov, Chairman & CEO of Mira Pharmaceutic ...